Michael Feld Sells 75 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $147.35, for a total transaction of $11,051.25. Following the sale, the executive vice president directly owned 21,084 shares in the company, valued at approximately $3,106,727.40. This represents a 0.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.94, for a total transaction of $11,243.56.
• On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $181.84, for a total transaction of $13,638.00.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $148.36 on Friday. The stock has a market capitalization of $40.88 billion, a P/E ratio of 37.56, a P/E/G ratio of 10.42 and a beta of 0.22. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a 50 day moving average of $151.84 and a 200-day moving average of $177.23. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.8%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Analysts Set New Price Targets

Several research analysts have commented on the company. Jefferies Financial Group lowered their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Argus lowered their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. The Goldman Sachs Group lowered their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday. Barclays boosted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Finally, Citigroup lowered their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research note on Tuesday, February 10th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $183.64.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently made changes to their positions in the business. Auto Owners Insurance Co raised its stake in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after buying an additional 4,223,149 shares in the last quarter. State Street Corp boosted its stake in Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after buying an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Becton, Dickinson and Company by 3.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock valued at $1,841,083,000 after purchasing an additional 336,110 shares during the period. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.